| __timestamp | Takeda Pharmaceutical Company Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 520990000000 | 17293000 |
| Thursday, January 1, 2015 | 535405000000 | 26470000 |
| Friday, January 1, 2016 | 558755000000 | 28307000 |
| Sunday, January 1, 2017 | 495921000000 | 30354000 |
| Monday, January 1, 2018 | 659690000000 | 32160000 |
| Tuesday, January 1, 2019 | 1089764000000 | 37571000 |
| Wednesday, January 1, 2020 | 994308000000 | 39951000 |
| Friday, January 1, 2021 | 1106846000000 | 50159000 |
| Saturday, January 1, 2022 | 1244072000000 | 54577000 |
| Sunday, January 1, 2023 | 1431505000000 | 61940000 |
| Monday, January 1, 2024 | 1431505000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Vericel Corporation from 2014 to 2023. Takeda, a global leader, showcases a staggering 175% increase in its cost of revenue over the decade, peaking at approximately 1.43 trillion in 2023. In contrast, Vericel, a smaller player, experienced a 258% rise, reaching around 61.94 million in the same year.
While Takeda's scale is immense, Vericel's growth trajectory is noteworthy, reflecting its strategic expansion in niche markets. The data highlights Takeda's consistent upward trend, with a notable surge post-2018, likely driven by strategic acquisitions and market expansion. Meanwhile, Vericel's steady growth underscores its focus on specialized therapies. Missing data for 2024 suggests ongoing developments, inviting further exploration into these companies' future strategies.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Vericel Corporation
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Perrigo Company plc
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Vericel Corporation
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Supernus Pharmaceuticals, Inc.